Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celecoxib/valacyclovir - Virios Therapeutics

Next Previous
X
Search
Drug Profile

Celecoxib/valacyclovir - Virios Therapeutics

Alternative Names: IMC-2; Valacyclovir/celecoxib - Virios Therapeutics

Latest Information Update: 16 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Virios Therapeutics
  • Class Antimigraines; Antineoplastics; Antipyretics; Antirheumatics; Antivirals; Branched-chain amino acids; Essential amino acids; Hypoxanthines; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; DNA-directed DNA polymerase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Post acute COVID 19 syndrome
  • Research Fibromyalgia

Most Recent Events

  • 08 Aug 2024 Adverse event data from the phase II PASC trial in Post-acute-COVID-19-syndrome released by Virios Therapeutics
  • 23 Jul 2024 Bateman Horne Center in collaboration with Virios Therapeutic completes enrolment in the phase II PASC trial in Post-acute-COVID-19-syndrome in USA (NCT06316843)
  • 22 Jan 2024 Virios Therapeutic plans a phase II trial for Post-acute-COVID-19-syndrome in the second half of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top